LU91902I2 - Bélatacept et ses dérivés pharmaceutiquement acceptables (NULOJIX®) - Google Patents

Bélatacept et ses dérivés pharmaceutiquement acceptables (NULOJIX®)

Info

Publication number
LU91902I2
LU91902I2 LU91902C LU91902C LU91902I2 LU 91902 I2 LU91902 I2 LU 91902I2 LU 91902 C LU91902 C LU 91902C LU 91902 C LU91902 C LU 91902C LU 91902 I2 LU91902 I2 LU 91902I2
Authority
LU
Luxembourg
Prior art keywords
amino acid
ctla4
bélatacept
nulojix
pharmaceutically acceptable
Prior art date
Application number
LU91902C
Other languages
English (en)
French (fr)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of LU91902I2 publication Critical patent/LU91902I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU91902C 2000-05-26 2011-11-16 Bélatacept et ses dérivés pharmaceutiquement acceptables (NULOJIX®) LU91902I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (1)

Publication Number Publication Date
LU91902I2 true LU91902I2 (fr) 2012-01-16

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91902C LU91902I2 (fr) 2000-05-26 2011-11-16 Bélatacept et ses dérivés pharmaceutiquement acceptables (NULOJIX®)

Country Status (41)

Country Link
EP (3) EP1248802B9 (instruction)
JP (1) JP4328525B2 (instruction)
KR (2) KR100895134B1 (instruction)
CN (2) CN101255192A (instruction)
AR (1) AR031699A1 (instruction)
AT (1) ATE271066T1 (instruction)
AU (2) AU6346601A (instruction)
BE (1) BE2011C041I2 (instruction)
BR (1) BRPI0111191B8 (instruction)
CA (1) CA2409748C (instruction)
CY (2) CY2011019I1 (instruction)
CZ (1) CZ304451B6 (instruction)
DE (2) DE60104282T2 (instruction)
DK (1) DK1248802T3 (instruction)
EC (1) ECSP024365A (instruction)
EE (2) EE05458B1 (instruction)
EG (1) EG24459A (instruction)
ES (2) ES2225549T3 (instruction)
FR (1) FR11C0053I2 (instruction)
GE (1) GEP20053658B (instruction)
HK (1) HK1048126B (instruction)
HU (2) HU228137B1 (instruction)
IL (1) IL152315A (instruction)
LT (1) LT5133B (instruction)
LU (1) LU91902I2 (instruction)
LV (1) LV12994B (instruction)
MX (1) MXPA02011534A (instruction)
MY (1) MY136113A (instruction)
NO (2) NO330797B1 (instruction)
PE (1) PE20011338A1 (instruction)
PL (1) PL206267B1 (instruction)
PT (1) PT1248802E (instruction)
RU (1) RU2283847C2 (instruction)
SI (1) SI1248802T1 (instruction)
SK (1) SK288131B6 (instruction)
TR (1) TR200402703T4 (instruction)
TW (2) TWI319405B (instruction)
UA (1) UA87432C2 (instruction)
UY (1) UY26723A1 (instruction)
WO (1) WO2001092337A2 (instruction)
ZA (1) ZA200208944B (instruction)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
PT1372696E (pt) * 2000-07-03 2008-10-24 Bristol Myers Squibb Co Métodos para o tratamento de doenças reumáticas utilizando uma molécula ctla4 solúvel
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
CA2482042A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
BR0317723A (pt) 2002-12-23 2005-11-22 Bristol Myers Squibb Co Processo de cultura de células de mamìfero para a produção de proteìna
AU2003303394B2 (en) * 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
CA2543484C (en) 2003-10-27 2014-02-04 Amgen Inc. Modulation of immune response to an immunogen with ctla-4 and tnfbp
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP1969007B1 (en) * 2005-12-20 2013-08-28 Bristol-Myers Squibb Company Compositions and methods for producing a composition
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
CN103709249B (zh) 2006-12-20 2016-02-24 Mmr全球公司 抗体及其制备和使用方法
ES2688721T3 (es) * 2007-11-01 2018-11-06 Astellas Pharma Inc. Polipéptidos y ácidos nucleicos inmunosupresores
ES2657220T3 (es) * 2008-10-02 2018-03-02 Aptevo Research And Development Llc Proteínas de unión multi-diana antagonistas de CD86
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
JP2014506482A (ja) 2011-02-23 2014-03-17 アムジエン・インコーポレーテツド Ｕｖｃ露光のための細胞培養培地およびそれに関連した方法
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
HK1209644A1 (en) * 2012-05-11 2016-04-08 Medimmune, Llc Ctla-4 variants
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
JP2015522026A (ja) * 2012-06-27 2015-08-03 オルバン バイオテック エルエルシー 糖尿病を処置するためのｃｔｌａ４融合タンパク質
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
CN106029896B (zh) 2014-01-13 2020-10-27 美国安进公司 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
SG11201610143VA (en) 2014-06-04 2017-01-27 Amgen Inc Methods for harvesting mammalian cell cultures
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
JP2018512856A (ja) 2015-04-17 2018-05-24 アルパイン イミューン サイエンシズ インコーポレイテッド 調整可能な親和性を有する免疫調節タンパク質
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
JP2018536404A (ja) 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
US11261233B2 (en) 2016-09-19 2022-03-01 OncoC4, Inc. CD80 and CD86 binding protein compositions and uses thereof
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
CN111031790A (zh) 2017-04-20 2020-04-17 E开创生物技术股份有限公司 产生基因修改的动物的方法
US11753458B2 (en) * 2017-10-10 2023-09-12 Alpine Immune Sciences, Inc. CTLA-4 variant immunomodulatory proteins and uses thereof
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
JP2022545917A (ja) 2019-08-27 2022-11-01 トニックス ファーマ リミテッド 修飾ｔｆｆ２ポリペプチド
MY193354A (en) 2019-12-06 2022-10-06 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
US12103960B2 (en) 2020-05-08 2024-10-01 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
JP2023530712A (ja) 2020-06-18 2023-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 未処理ｃ末端リジンを正確に測定するための重ペプチドアプローチ
CA3189533A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
JP2025500887A (ja) 2021-12-16 2025-01-15 ブリストル－マイヤーズ スクイブ カンパニー ウイルス不活化用界面活性剤
AU2023229163A1 (en) 2022-03-02 2024-09-12 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
EP0606217B2 (en) * 1991-06-27 2008-12-03 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
JP2003532370A (ja) * 1998-10-07 2003-11-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 新規なＴｈ２特異的分子およびその使用方法
PT1372696E (pt) * 2000-07-03 2008-10-24 Bristol Myers Squibb Co Métodos para o tratamento de doenças reumáticas utilizando uma molécula ctla4 solúvel

Also Published As

Publication number Publication date
TR200402703T4 (tr) 2004-11-22
ATE271066T1 (de) 2004-07-15
PT1248802E (pt) 2004-11-30
NO20025656L (no) 2002-11-25
PE20011338A1 (es) 2002-01-13
EE05458B1 (et) 2011-08-15
BRPI0111191B1 (pt) 2019-12-31
DE122011100063I1 (de) 2012-06-14
LT5133B (lt) 2004-05-25
PL366231A1 (en) 2005-01-24
SK288131B6 (sk) 2013-10-02
EE200200659A (et) 2004-06-15
KR100889887B1 (ko) 2009-03-24
FR11C0053I2 (fr) 2013-01-11
AU6346601A (en) 2001-12-11
LV12994B (en) 2003-08-20
JP4328525B2 (ja) 2009-09-09
DE60104282T2 (de) 2005-10-13
NO20025656D0 (no) 2002-11-25
EP1536234B1 (en) 2016-03-16
CN1441810A (zh) 2003-09-10
UA87432C2 (uk) 2009-07-27
TWI319405B (en) 2010-01-11
BE2011C041I2 (instruction) 2020-08-20
CN1309735C (zh) 2007-04-11
WO2001092337A3 (en) 2002-05-10
BR0111191A (pt) 2004-07-06
CA2409748C (en) 2008-09-16
MXPA02011534A (es) 2004-08-12
ECSP024365A (es) 2003-03-31
CN101255192A (zh) 2008-09-03
HK1071931A1 (en) 2005-08-05
JP2004511213A (ja) 2004-04-15
CY1117625T1 (el) 2017-04-26
IL152315A (en) 2010-04-15
CZ20023892A3 (cs) 2003-09-17
MY136113A (en) 2008-08-29
HUP0302201A2 (hu) 2003-10-28
KR20030009502A (ko) 2003-01-29
NO2011027I2 (instruction) 2011-12-15
NO2011027I1 (no) 2012-01-09
EE05557B1 (et) 2012-08-15
SK15702002A3 (sk) 2004-01-08
FR11C0053I1 (instruction) 2012-01-13
CA2409748A1 (en) 2001-12-06
NO330797B1 (no) 2011-07-18
DK1248802T3 (da) 2004-11-15
EP3029062A1 (en) 2016-06-08
BRPI0111191B8 (pt) 2021-05-25
ZA200208944B (en) 2004-02-13
IL152315A0 (en) 2003-05-29
RU2283847C2 (ru) 2006-09-20
LT2002114A (en) 2003-12-29
HU228137B1 (en) 2012-12-28
AU2001263466B2 (en) 2006-04-27
EE201100050A (et) 2011-10-17
HK1048126B (en) 2005-03-04
DE60104282D1 (de) 2004-08-19
EG24459A (en) 2009-07-16
HK1048126A1 (en) 2003-03-21
AR031699A1 (es) 2003-10-01
CZ304451B6 (cs) 2014-05-14
PL206267B1 (pl) 2010-07-30
AU2001263466C1 (en) 2006-10-26
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
HUP0302201A3 (en) 2010-01-28
CY2011019I1 (el) 2016-12-14
SI1248802T1 (en) 2005-02-28
ES2571852T3 (es) 2016-05-27
GEP20053658B (en) 2005-11-10
EP1536234A3 (en) 2009-06-03
ES2225549T3 (es) 2005-03-16
KR100895134B1 (ko) 2009-05-04
TW200906857A (en) 2009-02-16
EP1536234A2 (en) 2005-06-01
KR20070094019A (ko) 2007-09-19
EP1248802B9 (en) 2005-05-11
UY26723A1 (es) 2001-12-28
EP1248802B1 (en) 2004-07-14
TWI314933B (en) 2009-09-21
HUS1300012I1 (hu) 2016-08-29
WO2001092337A2 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
LU91902I2 (fr) Bélatacept et ses dérivés pharmaceutiquement acceptables (NULOJIX®)
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
AU5242000A (en) Nematicidal trifluorobutenes
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
AU3877500A (en) Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof
BR9906927A (pt) Proteìnas de neisseria meningitidis
DK1090039T3 (da) Peptidsammensætning som immunogen til behandling af allergi
SG160336A1 (en) Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
ATE331037T1 (de) Isoliertes frpb nukleinsäuremolekül und entsprechende impfstoff
WO2005042590A3 (fr) Derives amphiphiles de cyclodextrines, leur procede de preparation et leurs utilisations
DE59914314D1 (de) 2,3,3a,4,9,9a-HEXAHYDRO-8-HYDROXY-1H-BENZÄFÜINDOLE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL
CY1107483T1 (el) Παραγωγα πυριδαζινης, η χρηση τους ως φαρμακευτικα σκευασματα και η διαδικασια παρασκευης τους